Concolino G, Di Silverio F, Marocchi A, Bracci U
Eur Urol. 1979;5(5):319-22. doi: 10.1159/000473142.
Estradiol receptor (ER) and progesterone receptor (PR), found in experimental renal cancer as well as in normal human kidney and in human renal cell carcinoma (RCC), have been measured in 27 RCCs from patients submitted to surgery and endocrine therapy in an attempt to predict the response to progestational therapy. Of these 27 tumors 59% were positive for ER and 59% for PR; 37% were positive and 19% negative for both ER and PR. The follow-up of 23 patients showed that progestational therapy, started in 18 patients, has given favorable results in 14 patients and negative results in 3 patients with ER-PR- renal cancer. Antiestrogenic therapy, started soon after nephrectomy in 1 patient with ER+PR- renal cancer and lung metastases, failed since the patient died 8 months after surgery.
在实验性肾癌以及正常人类肾脏和人类肾细胞癌（RCC）中均发现了雌二醇受体（ER）和孕酮受体（PR）。为了预测对孕激素治疗的反应，对27例接受手术和内分泌治疗的肾细胞癌患者的上述受体进行了检测。在这27例肿瘤中，59%的ER呈阳性，59%的PR呈阳性；37%的ER和PR均呈阳性，19%的ER和PR均呈阴性。对23例患者的随访显示，18例患者开始接受孕激素治疗，其中14例疗效良好，3例ER-PR-肾癌患者疗效不佳。1例ER+PR-肾癌伴肺转移患者在肾切除术后不久开始接受抗雌激素治疗，但该患者术后8个月死亡，治疗失败。
